Fascioliasis hepatis complicated by obstructive jaundice is a rare but clinically challenging form of parasitic infection of the hepatobiliary system, associated with a high risk of diagnostic errors and severe complications. Therefore, the choice of appropriate surgical tactics with a focus on minimally invasive techniques is of particular importance. The aim of this study was to evaluate the efficacy of endoscopic diagnostic and treatment methods for obstructive jaundice of parasitic origin caused by Fasciola hepatica. Materials and Methods. In 2023, 28 patients with bile duct obstruction caused by Fascioliasis hepatis were treated at the Endomed Clinic (Fergana, Uzbekistan). All patients underwent early endoscopic retrograde cholangiopancreatography (ERCP) for diagnostic and therapeutic purposes, followed by endoscopic papillosphincterotomy and parasite removal. Results. In all cases, biliary obstruction was eliminated and clinical manifestations of obstructive jaundice regressed. The average hospital stay was 4.7±1.4 days. Open surgery was not required. Conclusions: Endoscopic minimally invasive techniques are an effective and safe treatment for obstructive jaundice of parasitic origin, reducing hospital stay and the risk of postoperative complications.

Liver fascioliasis, mechanical jaundice, biliary obstruction

Bakhshipour, F., Zibaei, M., Rokni, M. B., Miahipour, A., Firoozeh, F., Beheshti, M., Beikzadeh, L., Alizadeh, G., Aryaeipour, M., & Raissi, V. (2024). Comparative evaluation of real-time PCR and ELISA for the detection of human fascioliasis. Scientific reports, 14(1), 3865. https://doi.org/10.1038/s41598-024-54602-y

Çiçek M, Yalçın K, Bilden A, Çakır F, Akpolat N. Evaluation of the seroprevalence and the demographic and clinical findings of fascioliasis patients in the Dicle River Basin in Turkey: A nine-year experience at a university hospital. Eur. Rev. Med. Pharmacol. Sci. 2023;27:10831–10838. doi: 10.26355/eurrev_202311_34449.

Caravedo MA, Cabada MM. Human fascioliasis: Current epidemiological status and strategies for diagnosis, treatment, and control. Res. Rep. Trop. Med. 2020;11:149–158. doi: 10.2147/RRTM.S237461.

Guerrero-Espejo A, Bernad-Anso A. Incidence and geographical distribution of patients hospitalized with fascioliasis in Spain. Enferm Infecc Microbiol. Clin. 2020;38:257–262. doi: 10.1016/j.eimc.2019.08.004.

Aftab, A., Raina, O. K., Maxton, A., & Masih, S. A. (2024). Advances in diagnostic approaches to Fasciola infection in animals and humans: An overviews. Journal of helminthology, 98, e12. https://doi.org/10.1017/S0022149X23000950

Ibrahim, N., Abdel Khalek, E.M., Makhlouf, N.A., Abdel-Gawad, M., Mekky, M., Ramadan, H.K., Abu-Elfatth, A., El-Latif, N.A., Hassan, M.K., Eldeeb, R., Abdelmalek, M., Abd-Elsalam, S., Attia, H., Mohammed, A.Q. Aboalam, H., Farouk, M., & Alboraie, M. (2023). Clinical characteristics of human fascioliasis in Egypt. Scientific reports, 13(1), 16254. https://doi.org/10.1038/s41598-023-42957-7

Gandhi, P., Schmitt, E. K., Chen, C. W., Samantray, S., Venishetty, V. K., & Hughes, D. (2019). Triclabendazole in the treatment of human fascioliasis: a review. Transactions of the Royal Society of Tropical Medicine and Hygiene, 113(12), 797–804. https://doi.org/10.1093/trstmh/trz093